期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 54, 期 1, 页码 S108-S117出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2009.04.014
关键词
treatment; pulmonary arterial hypertension; PAH
资金
- NHLBI NIH HHS [R01 HL066012-07, R01 HL066012] Funding Source: Medline
Over the past 2 decades, pulmonary arterial hypertension has evolved from a uniformly fatal condition to a chronic, manageable disease in many cases, the result of unparalleled development of new therapies and advances in early diagnosis. However, none of the currently available therapies is curative, so the search for new treatment strategies continues. With a deeper understanding of the genetics and the molecular mechanisms of pulmonary vascular disorders, we are now at the threshold of entering a new therapeutic era. Our working group addressed what can be expected in the near future. The topics span the understanding of genetic variations, novel antiproliferative treatments, the role of stem cells, the right ventricle as a therapeutic target, and strategies and challenges for the translation of novel experimental findings into clinical practice. (J Am Coll Cardiol 2009;54:S108-17) (C) 2009 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据